Africa Vaccine Market Size, Share & Growth Forecast 2030

Africa Vaccine Market Size, Share & Growth Forecast 2030

Introduction

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically consists of a weakened, killed, or parts of the microorganisms, such as bacteria or viruses, that cause the disease. When a person is vaccinated, their immune system is exposed to these harmless forms or components of the pathogen, triggering an immune response. This response involves the production of antibodies and the development of memory cells, which "remember" the specific pathogen and enable a faster and more effective immune response if the individual is later exposed to the actual infectious agent.

The African vaccine market in 2025 highlights a critical economic paradox defined by high consumption volume but low market value. Valued at US$1.3 billion, Africa represents a meager 4% share of the global vaccine market by value, yet the continent consumes over 25% of global vaccine volume, requiring roughly 1.5 billion doses annually. This commercial gap is driven by a heavy reliance on externally subsidized, low-cost pediatric procurement programs. It leaves the region profoundly exposed, as 99% of its human vaccines are imported from manufacturers in Asia and Europe. In response, 2025 marked a pivotal year of structural transition. The African Union and the World Health Organization aggressively scaled institutional capital and technology transfers across fewer than 10 localized hubs in South Africa, Senegal, Morocco, Egypt, and Tunisia. These actions aimed to elevate the continent's 1% localized production footprint toward a sovereign target of 60% domestic manufacturing by 2040.

Global Africa Vaccine Market Revenue Analysis and Market Share analysis

In 2025, the African routine human vaccine market was valued at approximately US$1.3 billion, capturing a disproportionately low 4% share of the global vaccine market by value despite the continent consuming roughly 25% of global vaccine volume (~1.5 billion doses). This value-to-volume imbalance stems from Africa's severe over-reliance on heavily subsidized, low-cost pediatric procurement pools, with 99% of its total vaccine supply being imported primarily from manufacturing facilities in Asia and Europe. Throughout 2025, the market structure remained highly centralized with fewer than 10 active manufacturers spread across South Africa, Senegal, Morocco, Egypt, and Tunisia, yielding a local production footprint of just 1%. To counteract this vulnerability, 2025 served as a critical operational year for the African Union and the World Health Organization, as they aggressively deployed institutional funding and tech transfers to scale regional fill-and-finish projects under a broader mandate to supply 60% of the continent's vaccine needs locally by 2040.

The Africa Vaccine market is growing at a considerable growth rate due to the presence of several players globally as well as newly launched products. This has led the market to achieve a US$ 2,401.3 million market size in 2023.

The COVID-19 pandemic has also impacted the vaccine market, with 28.3% share and relatively revenue is US$ 950.0 million in 2023. The total revenue of the Africa vaccine market (including Covid Vaccine) in 2023 was US$ 3,352.3 million, while the estimated value in 2030 is US$ 4,343.6 million.

The Conjugate Vaccines acquires the highest market share by vaccine type segment due to its capability of converting TI-2 immune responses to TD immune responses and many others effective advantages with share of 38.1% in 2023. Also, Attenuated vaccines (Live Vaccines) is holding 2^nd number in vaccine segment with 25.7% share in 2023.

Similarly, within the vaccine category segment in Africa, human vaccines captured a larger share than veterinary vaccines, holding 79.3% of the market in 2023. This share is expected to increase during the forecast period (2024-2030) with a CAGR of 7.7%. The smaller profit from veterinary (animal) vaccines is due to their lower prices and the smaller market size compared to the human vaccine industry.

The Nigeria Country dominates the Africa Vaccine Market with a market value of US$ 593.4 million in 2023. This is due to the presence of high population and key players in introducing new products into the market.

Additionally, Ethiopia holds a smaller market share compared to Nigeria, with a 10.9% share in 2023, due to lower vaccine adoption.

The Africa vaccine market in Egypt is projected to experience a growth of 76 basis points, increasing from 3.5% to 4.2% over the forecast period from 2024 to 2030.

Additionally, during the forecast period (2024-2030), BPS for Conjugate Vaccines have decreased by (109) basis points, decreasing from 38.9% to 37%. In contrast, BPS for Attenuated vaccines (Live Vaccines) have increased by 71 basis points, increasing from 25.7% to 26.4%.

Top Market Players in Africa Vaccine Market

AstraZeneca

AstraZeneca is a global biopharmaceutical company that operates in the competitive pharmaceutical industry, focusing on researching, developing, manufacturing, and commercializing prescription drugs. The company aims to address unmet medical needs worldwide, offering a diverse portfolio of medications covering areas such as oncology, cardiovascular, respiratory, metabolic, and autoimmune diseases.

BioNTech SE

BioNTech, is a biotechnology company, has significantly expanded its global presence, with a notable focus on the African vaccine market. Recognizing the importance of local manufacturing for sustainable healthcare solutions, BioNTech gets on innovative to establish mRNA manufacturing capabilities in Africa. This effort saw the initiation of construction for a state-of-the-art manufacturing facility in Kigali, Rwanda, marking a significant milestone in the company's commitment to the continent.

Johnson & Johnson Inc.

In the African vaccine market, Johnson & Johnson stands as a multifaceted healthcare, offering medical devices, pharmaceuticals, and consumer packaged goods. Established in 1886 and headquartered in New Jersey, USA, the company's extensive portfolio spans research, development, manufacturing, and distribution across global healthcare sectors. Operating divisions operate in nearly every country worldwide, showcasing Johnson & Johnson's expansive reach and commitment to advancing healthcare solutions. Organized into three key segments - Consumer Health, Pharmaceutical, and MedTech - the company caters to diverse healthcare needs.

Merck & Co.

Merck & Co., Inc., also known as MSD, internationally, is a prominent global pharmaceutical company established in 1891. Merck & Co., Inc specializing in the discovery, development, manufacturing, and marketing of a wide array of pharmaceuticals, vaccines, biologic therapies, and animal health products. Merck & Co., Inc. maintains a significant presence in the African vaccine market, having distributed 203 million doses globally in 2022.

Moderna, Inc.

Moderna, Inc., is a biotechnology company founded in 2010, and is at the forefront of mRNA technology, developing innovative medicines. The company's mRNA platform directs cells to produce proteins with therapeutic benefits, targeting a broad spectrum of diseases. Moderna has evolved from a research-stage entity to a commercial enterprise with a diverse clinical portfolio, including vaccines and therapeutics in infectious diseases, immuno-oncology, rare diseases, autoimmune diseases, and cardiovascular diseases.Novartis AG

Novartis AG, a Swiss multinational pharmaceutical giant, boasts a diversified business portfolio encompassing pharmaceuticals, generics, eye care, and vaccines. Renowned for its global presence and groundbreaking healthcare solutions, Novartis stands as a key player in researching, developing, and commercializing innovative medical interventions. With a steadfast commitment to pioneering research and development, the company excels in therapeutic areas such as oncology, cardiovascular diseases, neuroscience, immunology, and respiratory diseases.

Pfizer Inc.

Pfizer Inc. established in 1849 and headquartered in New York, U.S., Pfizer is a research-based, global biopharmaceutical company contributed to extending and enhancing lives worldwide. Through the finding, development, manufacture, marketing, sale, and distribution of biopharmaceutical products, Pfizer applies science and global resources to bring therapies that significantly improve people's lives.Sanofi Pasteur

With over 46 years of presence in Africa, Sanofi has been established as a partner in the region's healthcare landscape. Sanofi delivers innovative healthcare solutions, since its inception in 1994, headquartered in Paris, France. With three principal activities spanning pharmaceuticals, consumer healthcare, and vaccines, Sanofi operates through 3 distinct segments: pharmaceuticals, vaccines, and consumer healthcare.

Besides, the vaccines segment, managed by Sanofi, directs solely on vaccines, managing commercial operations and dedicated research and development, production, and marketing activities for the company's vaccine operations.

Serum Institute of India

Serum Institute of India Pvt. Ltd. stands as the world's largest vaccine manufacturer, having produced and distributed over 1.5 billion doses globally, encompassing a wide range of vaccines including Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella, Pneumococcal, and Covid-19 vaccines. With approximately 65% of children worldwide receiving at least one Serum Institute-manufactured vaccine, the company's impact on global immunization efforts is substantial.

Biocad

BIOCAD, Russia's premier biotechnology powerhouse, has extended its innovative prowess into the African vaccine market, recognizing the pressing need for advanced healthcare solutions on the continent. With state-of-the-art research and development capabilities, coupled with ultra-modern pharmaceutical and biotechnological manufacturing facilities compliant with international standards, BIOCAD stands poised to revolutionize vaccine access and delivery in Africa.

Related Reports

Diphtheria, Pertussis, and Tetanus (DPT) Vaccine Market

Porcine Vaccine Market

MRNA Vaccine & Therapeutics Raw Material Market